Healio: Plant-based topical improves itch, quality of life among patients with atopic dermatitis by Gabrielle M. Grasso NEWS PROVIDED BY Alphyn Biologics October 8, 2024 Zabalafin hydrogel clinically improved itch and quality of life among pediatric and adult patients with atopic dermatitis, according to interim results presented at the European Academy of Dermatology and Venerology…
2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics September 28, 2024, 19:30 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 NEWS PROVIDED BY Alphyn Biologics Aug 27, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 27, 2024 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that data from its Phase 2a human clinical…
Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics Aug 21, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 21, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that it has received a notice of claims allowance from the U.S. Patent and Trademark…
Society for Pediatric Dermatology Poster Presentation: First-in-Human Phase 2 Trial of Zabalafin Hydrogel (AB-101a) – Itch and Quality of Life Pediatric Results NEWS PROVIDED BY Alphyn Biologics July 8, 2024, 19:30 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195